Core Insights - The Chinese innovative pharmaceutical industry is transitioning from scale expansion to value enhancement by the end of 2025, facing challenges such as crowded competition and homogeneity [1] Group 1: Innovation Strategy - The company emphasizes not blindly following trends but focusing on unmet clinical needs to build core competitiveness, marking a shift from follower to leader in innovation [2] - The strategy involves a balanced approach of leveraging clinically validated traditional targets while also investing in more innovative products with higher added value [2][3] Group 2: Research Focus Areas - The company is concentrating on three core areas: 1. Infectious diseases, where it has established a solid foundation and achieved significant results 2. Metabolic diseases, focusing on long-acting insulin and addressing unmet needs like fatty liver 3. Oncology, targeting gastrointestinal tumors and exploring new mechanisms such as bispecific antibodies and antibody-drug conjugates [3][4] Group 3: AI in Drug Development - The company has developed an AI drug discovery platform that combines over 20 years of laboratory data with external models, enhancing its competitive edge [6] - AI has significantly improved efficiency in drug development, exemplified by a project that reduced the time to enter clinical trials by 50% through AI pre-screening [7] Group 4: International Expansion - The trend of Chinese innovative drugs going overseas is increasing, driven by improved R&D capabilities and the need to cover costs for rare disease drugs in international markets [10] - The company has taken concrete steps in internationalization, including partnerships for drug development and plans to enter the U.S. market with its insulin product [11][12] Group 5: Market and Policy Considerations - The company highlights the importance of aligning clinical and market needs, focusing on diseases with high incidence but limited treatment options, and considering international markets for rare diseases [13]

Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 8% in early trading, attributed to a strategic partnership with Mirxes for early cancer screening and drug development [1] Group 1: Company Developments - Jingtai Holdings' stock price rose by 6.98% to HKD 10.12, with a trading volume of HKD 129 million [1] - The collaboration with Mirxes aims to integrate strengths in early detection and drug development, focusing on a "diagnosis and treatment integration" solution for prevalent cancers in Asia [1] Group 2: Research and Analysis - Shenwan Hongyuan released a report highlighting Jingtai Holdings' core technology in "physical computing + AI + robotics," establishing a complete closed loop for early drug development from algorithms to automated laboratories [1] - The company's business has expanded from AI drug development to a broader "AI4S" platform, showcasing the potential for technology transfer to new materials and demonstrating significant technological breadth and platform value [1] - The initial coverage of Jingtai Holdings has been rated as "Buy" by analysts [1]

Core Viewpoint - Crystal Technology Holdings (02228) saw a significant stock increase, rising over 8% in early trading, attributed to a strategic partnership with Mirxes for early cancer screening solutions [1] Group 1: Company Developments - Crystal Technology Holdings' stock price reached HKD 10.12, with a trading volume of HKD 129 million [1] - The collaboration with Mirxes aims to integrate strengths in early detection and drug development, focusing on a "diagnosis and treatment integration" solution for prevalent cancers in Asia [1] Group 2: Research and Analysis - Shenwan Hongyuan released a report highlighting Crystal Technology Holdings' core technology, which combines physical computing, AI, and robotics to create a complete closed loop for early drug development [1] - The company's business has expanded from AI drug development to a broader "AI4S" platform, showcasing the potential for technology transfer to new materials and demonstrating significant technological breadth and platform value [1] - The report initiated coverage with a "buy" rating for Crystal Technology Holdings [1]

Group 1 - The core viewpoint of the article highlights the significant collaboration between Mirxes and Jingtai Technology, aiming to integrate their strengths in early cancer detection and drug development to explore a "diagnosis and treatment integration" solution for high-incidence cancers in Asia [1] - Jingtai Holdings (02228) saw its stock price increase by over 8% in early trading, with a current price of 10.12 HKD and a trading volume of 129 million HKD [1] - Shenwan Hongyuan's research report indicates that Jingtai Holdings has established a complete closed loop for early drug development, leveraging core technologies in "physical computing + AI + robotics" [1] Group 2 - The company's business has expanded from AI drug development to a broader "AI4S" platform, showcasing the potential for its underlying technology to accelerate innovation in drug development and migrate to new materials [1] - The report assigns a "buy" rating for Jingtai Holdings, reflecting confidence in its technological breadth and platform value [1]

Market Overview - In 2025, the A-share market experienced a structural "small bull" market, with 4,110 out of 5,176 stocks showing positive growth, and 523 stocks rising over 100% [1] - However, 40 stocks fell over 30%, with 7 stocks declining more than 40% [1] Worst Performing Stocks - The largest decline was seen in Shijing Technology, which dropped 50.99% in 2025, primarily due to a significant decrease in completed orders after entering the photovoltaic sector [3] - Kangle Weishi ranked second with a decline of 49.97%, continuing to face losses since 2013, with a net profit loss of 2.29 billion yuan in the first three quarters of 2025 [3][4] - Longda Meishi experienced a 48.11% drop, affected by a prolonged downturn in the pig cycle and intensified competition in the prepared food sector [3] Financial Performance - Kangle Weishi reported a revenue of 1.2763 million yuan in the first three quarters of 2025, a year-on-year increase of 106.53%, but still faced a net profit loss of 2.29 billion yuan [4] - The food and beverage sector saw a 9.69% decline in 2025, marking its fifth consecutive year of losses, with a cumulative drop of over 50% since the peak in 2021 [8][10] Industry Trends - The pharmaceutical and biotechnology sector showed signs of recovery in 2025, with an 11.94% increase, ending a four-year downtrend [10] - The food and beverage sector is expected to benefit from macro policies aimed at boosting domestic demand, with potential recovery in the white liquor and pre-processed food segments [10][11]

Group 1 - InSilico Medicine Cayman TopCo, referred to as "InSilico", officially listed on the Hong Kong Stock Exchange on December 30, with a pre-green shoe financing scale of HKD 22.77 billion and a post-green shoe financing scale of HKD 26.19 billion, assuming full exercise of the green shoe option [2] - This IPO is the largest for an AI pharmaceutical company in Hong Kong and the largest biotech IPO since 2025, reflecting strong market interest and recognition of InSilico's leadership in the AI pharmaceutical sector [2] - The offering attracted 15 cornerstone investors, including Eli Lilly, Tencent, Temasek, Schroders, UBS, Oak Tree Capital, E Fund, and Taikang Life, with international placement oversubscribed by 26.27 times and Hong Kong public offering oversubscribed by approximately 1427.37 times [2] Group 2 - CICC has been supporting InSilico since 2022, providing comprehensive cross-market services and leveraging its expertise in the TMT and pharmaceutical sectors to effectively promote the project and engage with global investors [3] - The project exemplifies CICC's capability in facilitating global capital operations for high-tech enterprises, with plans to continue providing comprehensive financial services to enhance the global competitiveness of international high-tech companies [3] - InSilico is a global AI-driven drug discovery and development company, utilizing its proprietary Pharma.AI platform to generate over 20 clinical or IND-stage assets, with three assets licensed to international pharmaceutical and healthcare companies, totaling a contract value of up to USD 2.1 billion [3]

Policy Developments - The National Health Commission and 13 other departments announced the "Five Health Promotion Action Plan" for children and adolescents, aiming to improve health in areas such as obesity, myopia, psychological behavior abnormalities, spinal deformities, and dental caries by 2026-2030 [2] Drug and Medical Device Approvals - Aosheng Pharmaceutical received approval for the market launch of the raw materials for Palbociclib and Dapagliflozin, which will enhance the company's product line and competitiveness [4] - Aied Biological obtained a medical device registration certificate for its BRCA1/BRCA2 gene mutation detection kit for prostate cancer, marking the first approval for this indication in China [5] Capital Markets - Yingsi Intelligent successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 2.277 billion, becoming the first AI-driven biopharmaceutical company to list under the main board rules [7] - China Pharmaceutical announced a plan to acquire 70% of Shanghai Zezheng Pharmaceutical for RMB 525 million, focusing on improved drug development services [8] - Yuekang Pharmaceutical submitted an application for H-share issuance to the Hong Kong Stock Exchange [9] Industry Events - Guangdong Province will implement a "one registration for three days" policy in public medical institutions starting January 1, 2026, allowing patients to return for follow-up consultations without additional registration fees within three days [11] Company Developments - Jincheng Pharmaceutical signed a supplementary agreement regarding tax payment responsibilities with shareholders, clarifying compensation terms related to tax liabilities [12] - *ST Chang Pharmaceutical faced a court ruling rejecting its restructuring application, leading to the bankruptcy of its subsidiary and potential delisting risks due to financial misconduct investigations [14]

12月30日，英矽智能在港交所挂牌上市，收盘涨幅约为25%。上市前一日,暗盘一度上涨200%，收涨50%，公开发售获超1400倍认购。 英矽智能在本次IPO中的募资金额接近23亿港元，是2025年港股未盈利生物科技企业IPO中募资金额最高的。其中，礼来、淡马锡、施罗德等15家基石投资 者的认购比例约为39%，基石投资人覆盖了全球制药巨头、国际主权基金、大型资管公司、龙头公募、险资等多种类型。其中，礼来总部今年首次出现在港 股上市创新药企的基石投资人名单中。 能吸引诸多投资机构在自己的生态圈中占位，与英矽智能本身的AI制药属性高度相关。从礼来、罗氏等跨国药企加码，到英伟达近3年内跨界"狂投"近20家 AI医疗概念公司，在AlphaFold3等AGI技术进步的加持下，AI制药的临界点正在到来。 2023年开始在国内谋求上市至今，历经4次递表，英矽智能终于成功上市，这也是资本市场对AI制药从质疑到认可，最终锚定其为确定性赛道的缩影。 平台能力验证 全明星基石阵容、AI制药标的稀缺，都让英矽智能备受市场关注。而支撑其市值和股价表现的，还是其自身业务基本面。 英矽智能最核心的AI药物发现及开发平台Pharma.AI，具 ...

Group 1 - The financing activities in the biopharmaceutical sector are experiencing a resurgence, indicating an improvement in the investment environment as multiple companies disclose financing progress [1] - Beijing Ruifen Biotechnology Co., Ltd. completed a C round financing of over 100 million yuan, aimed at commercial expansion and capacity construction [1] - Shanghai Xinguang Biopharmaceutical Co., Ltd. secured A1 round financing of several tens of millions of yuan, focusing on regenerative peritoneal dialysis products [1] Group 2 - The biopharmaceutical industry saw a significant drop in financing from 200 billion yuan in 2020 to an expected 20 billion yuan in 2024, suggesting a transition out of the "capital winter" into a rational development phase [1] - Professor Tian Lihui from Nankai University noted that the ongoing financing trend represents a rational recovery cycle for China's biopharmaceutical primary market, with a focus on core areas like AI drug development and gene therapy [2] - The value realization path in the industry has undergone a historic shift, with licensing-out transactions surpassing primary market financing as the main channel for validating the value of Chinese innovative drugs [2] Group 3 - Current investment trends show a preference for companies with strong original technologies, as evidenced by Xinguang Biopharmaceutical's rapid financing rounds due to its leading dialysis liquid regeneration technology [3] - The investment environment is in a recovery and structural optimization phase, with a shift away from valuation bubbles towards focusing on clinical data validation and clear commercialization paths [3] - The resurgence in financing activity is seen as a positive signal for the industry, promoting the completion of key clinical trials and capacity construction for quality projects [3]

《星岛》见习记者 黄冬艳 广州报道 12月30日，港股市场在年终再度迎来IPO扎堆上市的热潮，英矽智能、林清轩、迅策、卧安机器人、美 联股份、五一视界（51WORLD）六家公司同日敲钟，挂牌港交所。其中有着AI制药概念光环的英矽智 能（03696.HK），在公开发售时，于香港已录得约1427.37倍超额认购，最终上市发行价定为24.05港元/ 股，募集资金总额22.77亿港元，成为年内募集资金最高的港股生物医药IPO。 据悉，暗盘阶段英矽智能一度涨超200%，最高报价72.3港元/股，最终收报36.86港元/股，涨幅53.3%。 12月30日当天，英矽智能亦一路高开高走，截至当日收盘报29.98港元/股，涨幅24.66%，总市值167.11 亿港元。 基石投资者方面，英矽智能此次上市引入了包括礼来、腾讯、淡马锡、施罗德、瑞银、橡树资本、易方 达、泰康人寿等在内的15家全球化基石投资者，涵盖全球制药龙头、互联网巨头、国际主权基金与大型 资管机构等。 英矽智能联合首席执行官兼首席科学官任峰博士表示，AI的价值远不止于降本增效，更在于持续拓展 源头创新的边界；资本市场的支持，将助力英矽智能加快AI平台迭代、优化管线 ...